Astria Therapeutics Launches Phase 3 ALPHA-ORBIT Trial of Navenibart for Hereditary Angioedema Astria Therapeutics, Inc. (Nasdaq: ATXS), a biopharmaceutical company dedicated to developing transformative therapies for allergic and immune diseases,…
Adagio Medical Announces Restructuring to Accelerate US IDE Trial and Innovation Adagio Medical Holdings, Inc. (Nasdaq: ADGM), a leader in catheter ablation technologies for treating cardiac arrhythmias, today announced a…
Cardinal Health Releases New ESG Report Cardinal Health has published its Fiscal 2024 Environmental, Social, and Governance (ESG) Report, providing an overview of the company’s progress in key areas that…
CVS Pharmacy® Launches Enhanced Flu Testing and Treatment As flu cases continue to rise across the U.S., CVS Health® (NYSE: CVS) has announced enhanced flu testing and treatment options at…
Alaska Behavioral Health Partners with Netsmart for Integrated Healthcare Netsmart has announced that Alaska Behavioral Health (AKBH), the premier provider of mental health services in Alaska, has chosen the Netsmart…
Innovaccer Partners with Sacramento to Transform SHIE for Medi-Cal & Justice Populations Innovaccer Inc., a leading AI-driven healthcare company, has announced a partnership with the Sacramento County Department of Health…
Avitia Launches AI Platform for On-Site Rapid Cancer Screening Avitia, an innovative company specializing in AI-powered cancer screening and treatment identification, has announced a $5 million investment from PacBridge Capital…
Scale Biosciences Unveils Five Single Cell Profiling Products for Scalable RNA Studies Scale Biosciences (Scale Bio™), a leader in scalable single cell analysis, has announced the launch of its QuantumScale…
Summit Therapeutics Reports Q4 and 2024 Full-Year Financial and Operational Results Summit Therapeutics Inc. (NASDAQ: SMMT) has provided an update on its operational progress and financial results for the fourth…
Celltrion Gets EC Approval for Avtozma® (CT-P47), Biosimilar to RoActemra® Celltrion announced today that it has received marketing authorization from the European Commission (EC) for Avtozma® (CT-P47), a biosimilar referencing…
KalVista to Present New Sebetralstat Data at AAAAI 2025 Annual Meeting KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) has announced that six of its abstracts have been accepted for presentation at the…
Covalon Reports Fourth Straight Quarter of Revenue Growth and Positive Earnings Covalon Technologies Ltd. (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its financial results for the…